Skip to main content
SpringerLink
Log in

Caspofungin

A Review of its Use in the Treatment of Fungal Infections

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Caspofungin (Cancidas®) is the first of a new class of antifungal agents, the echinocandins, that inhibit the synthesis of the fungal cell wall component β-(l,3)-D-glucan. Caspofungin is administered once daily by slow intravenous infusion and is used to treat infections caused by Candida spp. and Aspergillus spp.

Caspofungin is a valuable new antifungal agent with a novel mechanism of action. In comparative clinical trials, caspofungin was no less effective than liposomal amphotericin B in the empirical treatment of neutropenic patients with persistent fever, amphotericin B deoxycholate in the treatment of invasive candidiasis or fluconazole in the treatment of oesophageal candidiasis. Caspofungin also displayed broadly similar efficacy to amphotericin B deoxycholate in oesophageal or oropharyngeal candidiasis and was effective as salvage therapy in patients with invasive aspergillosis who were refractory to or intolerant of standard therapy. The tolerability profile of caspofungin was similar to that of fluconazole and superior to that of amphotericin B deoxycholate and liposomal amphotericin B. Therefore, in the appropriate indications, caspofungin is a viable alternative to amphotericin B deoxycholate, liposomal amphotericin B or fluconazole.

Pharmacological Properties

Caspofungin blocks the synthesis of β-(l,3)-D-glucan, an essential component of the cell wall of many fungi, resulting in osmotic disruption of the fungal cell. Caspofungin is most active in vitro against Candida spp., for which it is fungicidal, and Aspergillus spp., for which it is generally fungistatic. A target susceptibility breakpoint of 1 μg/mL for caspofungin against Candida spp. has been suggested based on in vitro susceptibility testing, although this has not been correlated with clinical outcome. Caspofungin was effective in a variety of animal models of disseminated candidiasis, including those caused by azole-resistant strains, and invasive aspergillosis. The in vitro development of resistance to caspofungin is rare.

As the oral bioavailability of caspofungin is poor (<0.2%), the drug is administered by slow intravenous infusion over 1 hour. Single doses of 50 and 70mg produced mean peak (1 hour) plasma concentrations of 7.6 and 12.3 μg/mL and trough (24 hour) concentrations of 0.8 and 1.3 μg/mL. Steady state was reached after 14–21 days of multiple-dose administration. Plasma clearance of caspofungin is slow and is determined primarily by the distribution of drug into tissues, notably hepatocytes, rather than by the rate of metabolism or excretion. Caspofungin is slowly metabolised in the liver and dosage reduction is recommended in patients with moderate hepatic insufficiency. Excretion was minimal in the first 2 days following a single dose of radiolabelled caspofungin, and excretion in urine and faeces peaked at 6–7 days. Caspofungin does not readily interact with the cytochrome P450 system or P-glycoprotein. However, pharmacokinetic interactions between caspofungin and tacrolimus, ciclosporin (cyclosporin), rifampicin (rifampin) and other inducers of drug clearance have been reported.

Therapeutic Efficacy

In a head-to-head comparison, caspofungin 50 mg/day, following a 70mg loading dose on day 1, was no less effective than liposomal amphotericin B 3 mg/kg/day in the empirical treatment of presumed fungal infection in patients with neutropenia and persistent fever despite antibacterial therapy. Both treatments produced an overall favourable response in 34% of patients.

Caspofungin 50 mg/day was no less effective than fluconazole 200 mg/day in the treatment of adult patients (mostly HIV-infected) with oesophageal candidiasis. The efficacy of caspofungin 50 mg/day was also broadly similar to that of amphotericin B deoxycholate 0.5 mg/kg/day in the treatment of oesophageal or oropharyngeal candidiasis in two phase II trials not powered to allow formal efficacy comparisons.

Similarly, caspofungin 50 mg/day, following a loading dose of 70mg on day 1, was no less effective than amphotericin B deoxycholate 0.6–0.7 mg/kg/day in the treatment of patients with invasive candidiasis, mostly candidaemia. The respective favourable response rates were 73% and 62% of patients.

In two noncomparative studies, salvage therapy with caspofungin 70mg on day 1 followed by 50 mg/day thereafter was effective in 44% and 45% of patients with invasive aspergillosis who were refractory to or intolerant of standard therapy (polyenes or triazoles).

Analyses conducted in the US of drug acquisition costs and the costs of treating drug-induced nephrotoxicity predicted that caspofungin would have lower overall treatment costs than liposomal amphotericin B in febrile neutropenia and amphotericin B deoxycholate in invasive candidiasis.

Tolerability

Caspofungin was generally well tolerated in clinical trials. Serious adverse events were rare and only 11 of 979 caspofungin 50 mg/day recipients in prospective trials discontinued therapy as a result of probable drug-related adverse events.

The tolerability of caspofungin was superior to that of liposomal amphotericin B in febrile neutropenic patients, particularly with respect to nephrotoxicity and infusion-related events.

The tolerability profile of caspofungin was similar to that of fluconazole in patients with oesophageal candidiasis. Caspofungin was better tolerated than amphotericin B deoxycholate in patients with oesophageal, oropharyngeal or invasive candidiasis, particularly with respect to fever, chills, nausea, vomiting, infusion-related events, elevated serum creatinine, hypokalaemia, elevated blood urea nitrogen and decreased haemoglobin, each of which had a significantly higher incidence with amphotericin B deoxycholate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Table IV
Table V

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Denning DW. Echinocandin antifungal drags. Lancet 2003 Oct 4; 362(9390): 1142–51

    Article  PubMed  CAS  Google Scholar 

  2. Ullmann AJ. Review of the safety, tolerability, and drag interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 2003; 19(4): 263–71

    Article  PubMed  CAS  Google Scholar 

  3. Keating GM, Figgitt DP. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drags 2003; 63(20): 2235–63

    Article  CAS  Google Scholar 

  4. Pittet D, Wenzel RP. Nosocomial bloodstream infections: secular trends in rates, mortality, and contribution to total hospital deaths. 1995 Jun 12; 155(11): 1177–84

    CAS  Google Scholar 

  5. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001 Sep 1; 33(5): 641–7

    Article  PubMed  CAS  Google Scholar 

  6. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998 Apr; 26(4): 781–803

    Article  PubMed  CAS  Google Scholar 

  7. Girmenia C, Martino P. New antifungal drugs and new clinical trials: interpreting results may be difficult. Curr Opin Oncol 2003 Jul; 15(4): 283–8

    Article  PubMed  CAS  Google Scholar 

  8. Klepser ME. Antifungal resistance among Candida species. Pharmacotherapy 2001; 21 (8 Pt 2): 124S–32S

    Article  PubMed  CAS  Google Scholar 

  9. Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drags 2001 Aug; 10(8): 1545–58

    Article  CAS  Google Scholar 

  10. Merck & Co. Inc. CANCIDAS® (caspofungin acetate) for injection [intravenous infusion (not for IV bolus injection)]: US prescribing information [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/c/cancidas/cancidas_pi.pdf [Accessed 2005 Mar 20]

  11. Merck Sharp & Dohme Ltd. Cancidas (caspofungin): summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/cancidas/cancidas.htm [Accessed 2005 Jun 8]

  12. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003 Jun 1; 36(11): 1445–57

    Article  PubMed  CAS  Google Scholar 

  13. Boucher HW, Groll AH, Chiou CC, et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64(18): 1997–2020

    Article  PubMed  CAS  Google Scholar 

  14. Paderu P, Park S, Perlin DS. Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob Agents Chemother 2004 Oct; 48(10): 3845–9

    Article  PubMed  CAS  Google Scholar 

  15. Pfaller MA, Messer SA, Boyken L, et al. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J Clin Microbiol 2004 Jul; 42(7): 3117–9

    Article  PubMed  CAS  Google Scholar 

  16. Geiss HK, Dilger S. The post-antifungal effect of caspofungin [abstract no. A-495]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego (CA)

  17. Manavathu EK, Ramesh MS, Baskaran I, et al. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004 Feb; 53(2): 386–9

    Article  PubMed  CAS  Google Scholar 

  18. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandins, azole and polyene antifungal against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000 Apr; 44(4): 1108–11

    Article  PubMed  CAS  Google Scholar 

  19. Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001 Jan; 45(1): 327–30

    Article  PubMed  CAS  Google Scholar 

  20. Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003 Aug; 41(8): 3623–6

    Article  PubMed  CAS  Google Scholar 

  21. Kurtz MB, Rex JH. Glucan synthase inhibitors as antifungal agents. Adv Protein Chem 2001; 56: 423–75

    Article  PubMed  CAS  Google Scholar 

  22. Osherov N, May GS, Albert NA, et al. Overexpression of Sbe2p, a golgi protein involved in cell wall formation confers resistance to caspofungin in Saccharomyces cerevisiae [abstract no. J-1843]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22–25; Chicago (IL), 399

  23. Schuetzer-Muehlbauer M, Willinger B, Krapf G, et al. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 2003 Apr; 48(1): 225–35

    Article  PubMed  CAS  Google Scholar 

  24. Petraitis V, Petraitiene R, Kelaher A, et al. Antifungal activity and safety of caspofungin against experimental disseminated candidiasis in persistently neutropenic rabbits [abstract no. M188]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego (CA)

  25. Graybill JR, Najvar LK, Luther MF, et al. Treatment of murine disseminated candidiasis with L-743, 872. Antimicrob Agents Chemother 1997 Aug; 41(8): 1775–7

    PubMed  CAS  Google Scholar 

  26. Graybill JR, Bocanegra R, Luther M, et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743, 872. Antimicrob Agents Chemother 1997 Sep; 41(9): 1937–9

    PubMed  CAS  Google Scholar 

  27. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997 Nov; 41(11): 2333–8

    PubMed  CAS  Google Scholar 

  28. Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosup-pressed mice. Antimicrob Agents Chemother 2000 Sep; 44(9): 2310–8

    Article  PubMed  CAS  Google Scholar 

  29. Louie A, Deziel M, Liu W, et al. AUC/MIC is the pharmacodynamic variable for caspofungin as determined in a non-neutropenic mouse model of candidiasis [abstract no. A-1572]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago (IL), 31

  30. MacCallum DM, Odds FC. Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection. Antimicrob Agents Chemother 2004 Dec; 48(12): 4911–4

    Article  PubMed  CAS  Google Scholar 

  31. Ju JY, Polhamus C, Marr KA, et al. Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice. Antimicrob Agents Chemother 2002 May; 46(5): 1240–5

    Article  PubMed  CAS  Google Scholar 

  32. Louie A, Deziel M, Liu W, et al. Kidney concentrations are critical in understanding the pharmacodynamics of caspofungin [abstract no. A-1573]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago (IL), 31

  33. Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004 Oct 15; 190(8): 1464–71

    Article  PubMed  CAS  Google Scholar 

  34. Bernard EM, Ishimaru T, Armstrong D. Low doses of the pneumocandin, L-743,872, are effective for prevention and treatment in an animal model of pulmonary aspergillosis [abstract no. F39]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans (LA)

  35. Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002 Aug; 46(8): 2564–8

    Article  PubMed  CAS  Google Scholar 

  36. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002 Jan; 46(1): 12–23

    Article  PubMed  CAS  Google Scholar 

  37. Douglas CM, Abruzzo G, Bowman JC, et al. Caspofungin alone or in combination with itraconazole reduces fungal burden in a neutropenic guinea pig model of disseminated aspergillosis [abstract no. M-1819]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego (CA)

  38. Douglas CM, Abruzzo GK, Anderson JW, et al. Delayed therapy with caspofungin acetate significantly reduced established organ burdens in immunosuppressed mice infected with Aspergillus fumigatus [abstract no. M-360]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago (IL), 432

  39. Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001 Dec; 45(12): 3474–81

    Article  PubMed  CAS  Google Scholar 

  40. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard (NCCLS document M27-A [ISBN 1-56238-328-0]). Wayne (PA): National Committee for Clinical Laboratory Standards, 1997

    Google Scholar 

  41. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard — second edition (NCCLS document M27-A2 [ISBN 1-56238-469-4]). Wayne (PA): National Committee for Clinical Laboratory Standards, 2002

    Google Scholar 

  42. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard (NCCLS document M38-A [ISBN 1-56238-470-8]). Wayne (PA): National Committee for Clinical Laboratory Standards, 2002

    Google Scholar 

  43. Odds FC, Motyl M, Andrade R, et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004 Aug; 42(8): 3475–82

    Article  PubMed  CAS  Google Scholar 

  44. Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004 Jul; 42(7): 3142–6

    Article  PubMed  CAS  Google Scholar 

  45. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003 Oct; 47(10): 3149–54

    Article  PubMed  CAS  Google Scholar 

  46. Espinel-Ingroff A, Pfaller M, Messer SA, et al. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J Clin Microbiol 2004 Feb; 42(2): 718–21

    Article  PubMed  CAS  Google Scholar 

  47. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997 Nov; 41(11): 2326–32

    PubMed  CAS  Google Scholar 

  48. Barchiesi F, Schimizzi AM, Fothergill AW, et al. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999; 18: 302–4

    PubMed  CAS  Google Scholar 

  49. Vazquez JA, Lynch M, Boikov D, et al. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997 Jul; 41(7): 1612–4

    PubMed  CAS  Google Scholar 

  50. Ernst EJ, Klepser ME, Ernst ME, et al. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999; 33: 75–80

    Article  PubMed  CAS  Google Scholar 

  51. Johnson EM, Goldstein BP, Davey KG, et al. Comparison of the in vitro activity of anidulafungin with amphotericin B, caspofungin, fluconazole, itraconazole and voriconazole against a panel of 780 yeast isolates obtained from five European centres [abstract no. P513]. Clin Microbiol Infect 2004 May; 10 Suppl. 3: 113

    Google Scholar 

  52. Pfaller MA, Messer SA, Boyken L, et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol 2003 Dec; 41(12): 5729–31

    Article  PubMed  CAS  Google Scholar 

  53. Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002 Mar; 46(3): 739–45

    Article  PubMed  CAS  Google Scholar 

  54. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 2003 Jan; 41(1): 403–9

    Article  PubMed  CAS  Google Scholar 

  55. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echino-candin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002 Sep; 46(9): 3001–12

    Article  PubMed  CAS  Google Scholar 

  56. Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (l,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994 Jul; 38(7): 1480–9

    Article  PubMed  CAS  Google Scholar 

  57. Hernandez S, Lopez-Ribot JL, Najvar LK, et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004 Apr; 48(4): 1382–3

    Article  PubMed  CAS  Google Scholar 

  58. Moudgal V, Little T, Boikov D, et al. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005 Feb; 49(2): 767–9

    Article  PubMed  CAS  Google Scholar 

  59. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004 Sep; 48(9): 3407–11

    Article  PubMed  CAS  Google Scholar 

  60. Stevens DA, White TC, Perlin DS, et al. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 2005 Mar; 51(3): 173–8

    Article  PubMed  CAS  Google Scholar 

  61. Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004 Mar; 48(3): 815–23

    Article  PubMed  CAS  Google Scholar 

  62. Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005 May; 33(5): 676–82

    Article  PubMed  CAS  Google Scholar 

  63. Balani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000; 28(11): 1274–8

    PubMed  CAS  Google Scholar 

  64. Stone JA, Li S, Winchell G, et al. Population pharmacokinetics of caspofungin in candidiasis patients [abstract no. A-1571]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago (IL), 30

  65. Stone J, Holland S, Li S, et al. Effect of hepatic insufficiency on the pharmacokinetics of caspofungin [abstract no. A-14]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22–25; Chicago (IL)

  66. Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004 Nov; 48(11): 4306–14

    Article  PubMed  CAS  Google Scholar 

  67. Stone J, Holland S, Wickersham P, et al. Drug interactions between caspofungin and tacrolimus [abstract no. A-13]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22–25; Chicago (IL)

  68. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 Sep 30; 351(14): 1391–402

    Article  PubMed  CAS  Google Scholar 

  69. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002 Sep; 113(4): 294–9

    Article  PubMed  CAS  Google Scholar 

  70. Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002 Feb; 46(2): 451–7

    Article  PubMed  CAS  Google Scholar 

  71. Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001 Nov 1; 33(9): 1529–35

    Article  PubMed  CAS  Google Scholar 

  72. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 Dec 19; 347(25): 2020–9

    Article  PubMed  CAS  Google Scholar 

  73. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 Dec 1; 39(11): 1563–71

    Article  PubMed  CAS  Google Scholar 

  74. Kartsonis NA, Saah AJ, Lipka CJ, et al. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005 Apr; 50(3): 196–205

    Article  PubMed  Google Scholar 

  75. Wingard JR, Leather HL, Walsh TJ, et al. Pharmacoeconomic analysis comparing caspofungin to liposomal amphotericin B for empirical therapy in persistently febrile neutropenic patients [abstract no. O-1619 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC, 446

  76. Mansley EC, Sullivan E, Wood CA, et al. Caspofungin vs. amphotericin B deoxycholate: do the savings generated from reduced rates of impaired renal function offset the difference in drug costs? [abstract no. 165 plus poster]. 41st Annual Meeting of the Infectious Diseases Society of America; 2003 Oct 9–12; San Diego (CA), 55

  77. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004 Sep; 6(3): 110–6

    Article  PubMed  CAS  Google Scholar 

  78. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004 Jul; 34(1): 13–20

    Article  PubMed  CAS  Google Scholar 

  79. Morrissey CO, Slavin MA, O’Reilly MA, et al. Caspofungin as salvage therapy for invasive aspergillosis: results of the Australian Compassionate Access Program [abstract no. M-670]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC, 412

  80. Feldmesser M. New and emerging antifungal agents: impact on respiratory infections. Am J Respir Med 2003; 2(5): 371–83

    Article  PubMed  CAS  Google Scholar 

  81. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2004; 38(2): 161–89

    Article  Google Scholar 

  82. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42(10): 4419–31

    Article  PubMed  CAS  Google Scholar 

  83. Baddley JW, Moser SA. Emerging fungal resistance. Clin Lab Med 2004; 24(3): 721–35

    Article  PubMed  Google Scholar 

  84. Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: an echinocandin antifungal agent. Clin Ther 2002 Mar; 24(3): 351–77; discussion 329

    Article  PubMed  CAS  Google Scholar 

  85. Sobel JD. Practice guidelines for the treatment of fungal infections. Mycoses Study Group, Infectious Diseases Society of America. Clin Infect Dis 2000 Apr; 30(4): 652

    CAS  Google Scholar 

  86. Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003 Apr; 3(4): 230–40

    Article  PubMed  Google Scholar 

  87. Slavin MA, Szer J, Grigg AP, et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J 2004; 34(4): 192–200

    Article  PubMed  CAS  Google Scholar 

  88. Spanish Society of Chemotherapy and Spanish Society for Hematology and Hemotherapy. Prophylaxis and treatment of fungal infections in oncohematological patients [in Spanish]. Rev Esp Quimioter 2002 Dec; 15(4): 387–401

    Google Scholar 

  89. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 Mar 15; 34(6): 730–51

    Article  PubMed  Google Scholar 

  90. Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR 2004; 53 (No. RR-15): 1–112

    Google Scholar 

  91. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696–709

    Article  PubMed  CAS  Google Scholar 

  92. Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003 Oct; 82 Suppl. 2: S133–40

    Article  PubMed  Google Scholar 

  93. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive asper-gillosis. N Engl J Med 2002 Aug 8; 347(6): 408–15

    Article  PubMed  CAS  Google Scholar 

  94. National Library of Medicine. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ [Accessed 2005 Jul 19]

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Paul L. McCormack & Caroline M. Perry

Authors
  1. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline M. Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul L. McCormack.

Additional information

Various sections of the manuscript reviewed by: E.G. Arathoon, Clinica Familiar Luis Angel Garcia, Hospital General San Juan de Dios, Guatemala City, Guatemala; S.C. Deresinski, Department of Medicine, Stanford University, Stanford, California, USA; E.J. Ernst, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA; R. Lewis, University of Houston College of Pharmacy, Houston, Texas, USA; F.C. Odds, University of Aberdeen, School of Medical Sciences, Institute of Medical Sciences, Aberdeen, Scotland; M.A. Pfaller, University of Iowa College of Medicine, Iowa City, Iowa, USA; A.J. Ullmann, Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universitat, Mainz, Germany.

Data Selection

Sources: Medical literature published in any language since 1980 on ‘caspofungin’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE search terms were ‘caspofungin’ or ‘caspofungin acetate’. EMBASE search terms were ‘caspofungin’ or ‘caspofungin acetate’. AdisBase search terms were ‘caspofungin’ or ‘caspofungin acetate’ or MK-0991’ or ‘MK991’. Searches were last updated 1 September 2005.

Selection: Studies in patients with confirmed or probable mycoses who received caspofungin. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Caspofungin, candidiasis, aspergillosis, mycoses, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCormack, P.L., Perry, C.M. Caspofungin. Drugs 65, 2049–2068 (2005). https://doi.org/10.2165/00003495-200565140-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565140-00009

Keywords

Search

Navigation